Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. by Krastev, DB et al.
Coupling bimolecular PARylation biosensors with genetic screens to 1 
identify PARylation targets 2 
 3 
Dragomir B. Krastev1, Stephen J. Pettitt1, James Campbell1, Feifei Song1, 4 
Barbara E. Tanos2, Stoyno S. Stoynov3, Alan Ashworth1,4*, Christopher J. Lord1* 5 
 6 
1The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins 7 
Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK. 2The 8 
Cancer Therapeutics Division, The Institute of Cancer Research, London, SW3 9 
6JB, UK. 3The Institute of Molecular Biology, Bulgarian Academy of Sciences, 10 
Sofia 1113, Bulgaria, 4current address: The UCSF Helen Diller Family 11 
Comprehensive Cancer Center, 1450 3rd St, San Francisco, CA 94158, USA   12 
 13 
*Correspondence to: Chris.Lord@icr.ac.uk, Alan.Ashworth@ucsf.edu   14 
 15 
 16 
Keywords: PARylation, biosensor, tankyrase, transposon, genetic screen, 17 
centrosome 18 
  19 
PAR biosensors                                                                                                                 
 
 2
Abstract 20 
Poly (ADP-ribose)ylation is a dynamic protein modification that regulates multiple 21 
cellular processes. Here, we describe a system for identifying and characterizing 22 
PARylation events that exploits the ability of a PBZ (PAR-binding zinc finger) 23 
protein domain to bind PAR with high-affinity. By linking PBZ domains to 24 
bimolecular fluorescent complementation biosensors, we developed fluorescent 25 
PAR biosensors that allow the detection of temporal and spatial PARylation 26 
events in live cells. Exploiting transposon-mediated recombination, we integrate 27 
the PAR biosensor en masse into thousands of protein coding genes in living 28 
cells. Using these PAR-biosensor “tagged” cells in a genetic screen we carry out 29 
a large-scale identification of PARylation targets. This identifies CTIF 30 
(CBP80/CBP20-dependent translation initiation factor) as a novel PARylation 31 
target of the tankyrase enzymes in the centrosomal region of cells, which plays a 32 
role in the distribution of the centrosomal satellites. 33 
 34 
 35 
  36 
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Introduction  37 
Poly ADP-ribosylation (PARylation) is a highly dynamic and reversible post-38 
translation protein modification that is generated by a family of PAR polymerases 39 
(PARPs, ARTDs). The PARP superfamily encompasses 17 proteins, of which 40 
only PARP1, 2 and tankyrases (TNKS and TNKS2, also known as PARP5a and 41 
5b) display a clear PARP activity1. The remaining family members are mono 42 
ADP-ribose transferases or lack enzymatic activity. PARP1, 2 and 3 are nuclear 43 
proteins involved in DNA damage responses (DDR)2, while tankyrases regulate a 44 
variety of cellular processes including telomere maintenance3, Wnt signaling4 and 45 
mitotic progression5. The role of PARP1, 2 and 3 in the DDR provided the 46 
rationale for the discovery and development of clinical PARP inhibitors. In 47 
addition, tankyrase inhibition can suppresses constitutive Wnt signaling4, which 48 
has led to the discovery of a series of small molecule TNKS/TNKS2 inhibitors7,8. 49 
Given the burgeoning interest in the PARP superfamily enzymes as drug targets 50 
and their role as mediators of cellular signaling processes, identifying and 51 
characterizing the targets of these enzymes is critical.  52 
 53 
A number of studies have identified PARylation targets en masse by isolating 54 
proteins that bind to either anti-PAR antibodies or PAR-binding protein domains 55 
and identifying these by mass-spectrometry9. PARylation is often a transient 56 
modification, therefore some studies have used exposure to DNA damaging 57 
agents to enhance DNA damage-dependent PARylation, or suppression of PAR 58 
glycohydrase (PARG) to prevent PAR degradation10. An additional complication 59 
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of such studies is that PARylation is often induced on non-specific targets during 60 
in vitro cell lysis9, 11. Hence, additional approaches to detect and characterise 61 
PARylation targets are required. 62 
 63 
In this study, we describe a system for identifying and characterizing PARylation 64 
events that exploits the ability of PBZ (PAR-binding zinc finger) domains to bind 65 
PAR with high-affinity. By linking PBZ domains to bimolecularfluorescent 66 
complementation biosensors, we developed fluorescent PAR biosensors that 67 
allow the detection and localisation of PARylation events in live cells. Finally, by 68 
exploiting transposon mediated recombination, we integrated these PAR 69 
biosensors en masse into thousands of protein coding genes in living cells. Using 70 
these PAR-biosensor “tagged” cells in a genetic screen facilitates the large-scale 71 
identification of PARylation targets. Using this approach, we show that CTIF 72 
(CBP80/CBP20-dependent translation initiation factor) is a target of PARylation 73 
by tankyrases at centrosomes and plays a role in the distribution of the 74 
centrosomal satellites. 75 
 76 
Results 77 
PAR-binding domains serve as high-affinity cellular biosensors  78 
We aimed to develop a set of PAR-biosensors that could detect PARylation 79 
events in living cells. To do this, we exploited the PAR binding ability of PBZ 80 
(PAR-binding zinc finger) domains derived from either APLF (aprataxin PNK-like 81 
factor) or CHFR (checkpoint protein with FHA and RING domains) to bind PAR 82 
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with high affinity12. Although several other PAR-binding domains exist (such as 83 
macro and WWE domains), we selected PBZ domains for the development of 84 
biosensors for the following reasons: (i) their well-defined structure with the 85 
possibility to engineer precise point mutations that abolish PAR binding12, and (ii) 86 
their intermediate PAR binding affinity (weaker compared to macrodomains), 87 
which allows reversible binding (this is confirmed below), thus minimising the 88 
possibility of artefactual PAR stabilisation and interference with endogenous 89 
PARylation dependent processes. We fused the coding sequence of the APLF or 90 
CHFR PBZ domain to that of green fluorescent protein (GFP), generating PAR 91 
biosensors (Fig. 1a; from here onwards PBZ refers to the APLF domain and 92 
CHFR-PBZ will be explicitly written when it is used). We then compared the 93 
ability of PAR biosensors to detect DNA damage-induced PAR, when compared 94 
to PAR immunodetection with a commonly used anti-PAR antibody (10H). To 95 
elicit DNA damage-induced PARylation, we exposed HeLa cells to H2O2;; to 96 
reduce PAR, we exposed cells to the PARP1/2 inhibitor olaparib. In untreated 97 
cells, cells exposed to H2O2, or cells exposed to olaparib (Fig. 1b), the antibody 98 
and the biosensor signals were correlated (Spearman’s rank correlation, rs = 0.48, 99 
0.53 and 0.39 respectively) suggesting that the biosensor signal recapitulated the 100 
detection of PARylation shown by immunodetection (exemplary images are 101 
shown in Supplementary Fig. 1a).H2O2 exposure caused a close to two-fold 102 
increase in 10H PAR signal compared to the basal state, whilst olaparib 103 
treatment did not lead to any significant decrease in PAR signal (Fig. 1c), 104 
consistent with the notion that the 10H antibody predominately recognizes long 105 
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damage-induced PAR chains, but fails to detect endogenous PARylation. In 106 
contrast, the PAR biosensor revealed a broader dynamic range; H2O2 exposure 107 
caused an above five fold increase in the nuclear GFP intensity (Fig. 1c), whilst 108 
olaparib treatment led to a two fold decrease, resulting in a 12 fold difference 109 
between the absence and damage-induced PAR levels. 110 
 111 
We also assessed the ability of a PAR biosensor to monitor temporal changes in 112 
PARylation. To do this, we used PBZ-mRuby2 biosensor alongside a PARP1-113 
GFP expression construct; this allowed us to temporally co-monitor PARP1 and 114 
PAR localisation on UV microirradiated regions of cells. To eliminate any 115 
potential interference from endogenous PARP1, we carried out these 116 
experiments in PARP1–/– cells (Methods; Fig. 1d). Localised laser microirradiation 117 
led to a rapid localisation of PARP1 to the site of DNA damage (within 200 ms), 118 
followed 300 ms later by localisation of PAR at the same site (Fig. 1e). After 30-119 
60s, both the PARP1-GFP and PBZ-mRuby2 signals were reduced in a co-120 
ordinated fashion (Fig. 1f),likely reflecting reduction of PARP1 localisation and 121 
activity after the initial stages of DNA repair. The binding of the biosensor to the 122 
microirradiated site was rapid and reversible as shown by FRAP experiments 123 
(Supplementary Fig. 1c). To confirm the specificity of this effect, we used two 124 
mutant PARP1-GFP fusions Fig. 1g): a DNA-binding deficient mutant of PARP1 125 
with mutations of residues 43 and 44 that disrupt the ZnF1 domain (PARP1-126 
p.[43delM;44F>I] 13); or PARP1 with an E988K mutation that impairs catalytic 127 
activity. The PBZ-mRuby2 sensor signal at microirradiated regions was entirely 128 
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dependent upon wild-type PARP1 (Fig. 1hE). Exposure of HeLa cells to the 129 
clinical PARP inhibitor talazoparib also abolished the PBZ-mRuby2 sensor signal 130 
(Fig. 1i). Importantly, in this experiment PARP1-GFP was expressed at 131 
endogenous levels from a bacterial artificial chromosome (BAC) showing that 132 
PARP1 overexpression does not alter the behavior of the biosensor. Furthermore, 133 
using HeLa cells without any additional PARP1 expression, we assessed the 134 
behavior of PBZ-mRuby2 and CHFR-PBZ-GFP (Supplementary Fig. 1b). Both 135 
biosensors showed identical kinetics, confirming that the observed results are 136 
due to the dynamics of PAR modification rather than the specificities of the PBZ 137 
domain used. Taken together, this data suggested that the PAR biosensors we 138 
developed exhibited high sensitivity and PAR-dependent behavior and could be 139 
used to dynamically monitor the amount of cellular PARylation.  140 
 141 
Development and validation of bimolecular fluorescent complementation 142 
(BiFC) biosensors of PARylation 143 
The identification of PARylation targets via biochemical purification is confounded 144 
by the artefactual loss and gain of PARylation events during cell lysis9. As the 145 
PAR biosensors described above provided the ability to detect PARylation events 146 
in living cells, rather than in cell lysates, we assessed whether we could modify 147 
these so that they could be used in genetic screens to identify novel PARylation 148 
targets. To do this, we needed to solve two issues: (i) to design PAR biosensor 149 
systems that monitored the PARylation state of specific proteins, rather than the 150 
total amount of cellular PAR; and (ii) to design PAR biosensors that could 151 
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stabilize what might otherwise be relatively transient PARylation events. With 152 
these issues in mind, we designed a bimolecular fluorescent complementation 153 
(BiFC, “split-GFP”) approach, shown schematically in Fig. 2a. In BiFC 154 
approaches14, two non-fluorescent halves of a GFP molecule are expressed as 155 
fusion proteins with two query proteins; for example, the C-terminus of Venus 156 
GFP (VC) is fused to a query protein and the N-terminus of Venus GFP (VN) is 157 
fused to the PBZ domain (Fig. 2a). Hence, this would allow us to detect 158 
PARylation events by reconstituting a functional GFP molecule, when the query 159 
protein is PARylated. One advantage of such a system would be that whilst the 160 
PARylated state of some proteins might have biochemical half-lives in the range 161 
of seconds to minutes15,16, the half-life of Venus GFP, once formed by VC-VN 162 
complementation, is in the range of hours14, potentially stabilizing these events.  163 
 164 
To test this approach, we generated PBZ-VN and  PBZ-VC biosensors. 165 
Simultaneous introduction of these probes into HeLa cells in in the absence of 166 
exogenous DNA damage generated a characteristic pattern of multiple GFP-167 
positive nuclear foci (Fig. 2b). When used in isolation, neither PBZ-VN nor PBZ-168 
VC generated a detectable GFP signal. This suggested that the BiFC approach, 169 
compared to PBZ-GFP, might provide a more sensitive approach to monitoring 170 
PARylation events in situ.  171 
To assess the specificity of the BiFC approach, we generated sensors that 172 
contained four cysteine to alanine mutations within PBZ (equivalent to APLF 173 
amino acid positions p.C379A, C385A, C421A and C427A) known to abolish 174 
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PAR binding12; we termed these probes as PBZ-4A-VN, and PBZ-4A-VC. The 175 
introduction of these mutations abolished the formation of GFP-positive nuclear 176 
foci (Fig. 2b). Co-staining of the cells with a PAR-binding reagent (MABE1031, 177 
Millipore; Fig. 2b, red) showed that only the co-expression of the wild type PBZ 178 
probes led to PAR stabilization, while this was not the case for single probes or 179 
the PBZ-4A co-expression (quantification of this effect is shown in Fig. 2c). The 180 
split-GFP PBZ biosensor showed around 6-fold increase in PARylation, while a 181 
PARylation inducing treatment (10 min of 1 mM H2O2) showed 3-4 fold induction. 182 
Importantly, in all the subsequent experiments shown in Fig. 3, 4 and 5 to detect 183 
PARylation on target proteins, we express only one PBZ construct (typically 184 
PNZ-VN), which does not lead to PAR stabilization on its own.  185 
We introduced these sensors into PARP1–/– CAL51 cells and found that the 186 
absence of PARP1 prevented the detection of both GFP-positive nuclear foci and 187 
localized microirradiation PAR/GFP signal (Fig. 2d,e). This observation was 188 
therefore consistent with the central role of PARP1 as a nuclear PARP enzyme 189 
associated with the response to DNA damage17.  Consistent with this observation, 190 
we found that the PARP1/2 inhibitor olaparib reduced PBZ-VC + PBZ-VN nuclear 191 
foci, whilst a potent PARP5A/B (Tankyrase) inhibitor ICR-TNKS-001 (ref. 8) did 192 
not (Fig. 2d). 193 
Microirradiation experiments demonstrated that PBZ-VC + PBZ-VN could also 194 
monitor the temporal increase and then decrease in PARylation associated with 195 
microirradiation (Fig. 2e). In this case, only the wild type PBZ constructs, 196 
transfected in PARP1 wild type cells, showed efficient recruitment, showing the 197 
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dependence of this on the presence of PARP1. We believe that the kinetics of 198 
recruitment in these experiments reflect the properties of recruitment of the split-199 
GFP PBZ probes rather than in situ assembly of the GFP molecules. The 200 
formation of a mature GFP fluorophore in situ of assembly is typically observed in 201 
10 min (as discussed in Fig. 2f)18, hence the signal detection in the range 202 
seconds is likely a reflection of the recruitment of a fraction of pre-assembled 203 
GFP molecules. ThePBZ-4A-VN + PBZ-4A-VC sensors did not detect this 204 
dynamic PAR signal (Fig. 2e). In addition, the accumulation and dissipation of 205 
PAR was also not detected when PBZ-VN+PBZ-VC sensors were used in 206 
PARP1–/– cells, suggesting once more that this PAR signal was PARP1 207 
dependent (Fig. 2e). These kinetics were identical to those observed with the 208 
PBZ-GFP sensor (Fig. 1f) suggesting that the fusion into the BiFC does not alter 209 
the recognition and recruitment to PARP1-mediated PARylation sites.  210 
 211 
Using PBZ-VN+PBZ-VC sensors to detect the temporal response to PARP1/2 212 
inhibitor exposure (talazoparib) GFP foci were found in the cytoplasm (Fig. 2f, 213 
yellow arrows) but were less frequent in the nucleus; when talazoparib was 214 
removed from the tissue culture media, nuclear GFP foci reformed within minutes 215 
(Fig. 2f, red arrows), whilst the frequency and intensity of cytoplasmic PAR foci 216 
was reduced. One explanation for this effect might be that the cytoplasmic GFP 217 
foci represented non-PARP1/2 mediated PARylation events (by PARP enzymes 218 
such as tankyrases, PARP4 and/or PARP10/14/16, which are not inhibited under 219 
these conditions), while nuclear GFP foci represented PARP1/2 mediated 220 
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PARylation; upon the removal of talazoparib, there is a rapid shift of PARylation 221 
from being mostly cytoplasmic to mostly nuclear due to the reactivation of 222 
PARP1. It should be noted that the possibility that talazoparib induces 223 
cytoplasmic stress granules, which are enriched in PAR, cannot be excluded as 224 
an alternative explanation.  The appearance of the nuclear foci coincides with the 225 
time of GFP fluorophore maturation in situ of the split-GFP assembly, which is 226 
around 10 min18, and it is unlikely to be due to sensor diffusion as this is a rather 227 
fast process (as assessed in Supplementary Fig. 1c).  228 
 229 
Lastly, we assessed whether the BiFC sensors could identify known PARylation 230 
events associated with PARP superfamily enzymes other than PARP1/2. To do 231 
this, we generated VC fused sensors for four “query” protein PARylation targets 232 
of Tankyrase (PARP5A/B, TNKS/TNKS2): AXIN4; TERF1 (aka TRF1)3; TNKS2 233 
itself (amino acids 800-1161, encompassing the SAM and CAT domains of the 234 
protein)4; and GLUT419. These query protein-VC sensors were introduced into 235 
HeLa cells alongside either PBZ-VN or PBZ-4A-VN (Fig. 2g). In each case, 236 
combining the PBZ-VN sensor with a query protein-VC revealed a detectable 237 
fluorescent signal that had the expected cellular localization pattern (cytoplasmic 238 
degradosomes for AXIN and TNKS2, nuclear for TERF1, perinuclear and Golgi-239 
like for GLUT4, Fig. 2f). In contrast, the PBZ-4A-VN biosensor generated only a 240 
marginally detectable fluorescent signal. We validated these signal by 241 
immunostaining with antibodies recognizing the endogenously expressed 242 
proteins (TERF1 and GLUT4 shown in Supplementary Fig. 2b,c), which revealed 243 
PAR biosensors                                                                                                                 
 
 12
partial or complete overlap of both signals. This suggests that the biosensor 244 
recognizes, in situ, only the PARylated fraction of the protein. It is particularly 245 
clear in the case of TERF1 (Supplementary Fig. 2b), which the antibody 246 
recognized throughout the nucleoplasm with some enrichment at the telomeres, 247 
while the biosensor signal is predominantly telomeric, which is where TRF1 is 248 
being PARylated3.  Furthermore, CHFR-PBZ-VN biosensor showed virtually 249 
identical pattern to PBZ-VN, strengthening these observations.  250 
Taken together, we concluded that these BiFC sensors demonstrated sufficient 251 
specificity for the PARylation state of a series of proteins and could be used to 252 
identify novel PARylation targets in situ, as described below. 253 
 254 
A BiFC based genetic screen identifies novel PARylation targets  255 
Using the BiFC sensors, we designed a genetic screening system aimed at 256 
identifying novel PARylation targets. The screening approach involved (Fig. 3a): 257 
(i) generating cellular libraries where each cell contained a VC coding sequence 258 
integrated into an endogenous gene by the use of a gene trap transposon20; (ii) 259 
introducing a PBZ-VN sensor into this cell library; (iii) selecting cells with VC-VN 260 
detectable PARylation events by FACS GFP-positive cells; and (iv) identifying 261 
the VC-containing gene by deep sequencing of genomic DNA flanking the 262 
transposon. 263 
We relied upon the ability to integrate an in-frame VC coding sequence into 264 
multiple endogenous genes in any given cell population. This generated a 265 
population of cells where the expression of query gene-VC fusion was largely 266 
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controlled by the native promoter and enhancer DNA sequences, rather than 267 
driving the transcription of query protein-VC fusions from a plasmid-based cDNA. 268 
Gene trap transposons provide an effective way of generating such gene fusion 269 
events within endogenous genes and so we adapted a Tol2-based UPATrap 270 
vector to encompass a VC-coding sequence (a schematic of how the gene 271 
trapping events occur is shown on Fig. 3b). Because Tol2 is a sequence-272 
independent cut-and-paste transposon21, only one of the two alleles of a gene is 273 
likely to be trapped, which implies that there would not be detrimental cellular 274 
effects because of the second allele. We used the previously published 275 
UPATrap21, which contains two functional DNA cassettes: (i) at the 5′-end, a 276 
promoterless splice acceptor (SA)-IRES-GFP-polyA sequence; and (ii) at the 3′-277 
end, a promoter-driven NeoR (G418 resistance) coding gene with a 3′ splice 278 
donor sequence (SD). We modified UPATrap in three significant ways to allow 279 
the generation of protein fragments fused to VC: (Supplementary Fig. 3a): (1) by 280 
replacing the IRES-GFP sequences with a VC-coding sequence, generating a 281 
SA-VC-polyA cassette; (2) by generating three different open reading frames of 282 
the resultant transposon (UPATrap-VC 1, 2 and 3); and (3) by removing the IRES 283 
sequence in the NeoR cassette. Removing the IRES, which suppresses the 284 
nonsense mediated decay of fusion transcripts, biases the selection of resistance 285 
towards the integration of the transposon in the 3’ of the captured genes (see 286 
Methods).  287 
 288 
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To validate the gene trap ability of these modified transposons, we also 289 
generated an UPATrap-GFP version (full-length GFP in place of the VC), 290 
andcotransfected this with transposase-expressing plasmid into both HeLa and 291 
CAL51 tumour cells. After neomycin selection, we found that 19% of CAL51 292 
neomycin-resistant (Neor) clones and 43% of HeLa Neor clones were GFP-293 
positive. By isolating individual colonies from GFP-positive CAL51 cells, we 294 
found that each colony exhibited a different localization of the GFP signal (Fig. 295 
3c), suggesting that the transposon had trapped different genes in each case. On 296 
the basis of these successful validation experiments, we generated gene trapped 297 
CAL51 cell libraries (i.e. populations of cells with the gene trap in different genes 298 
in different cells) using UPATrap-VC 1, 2 and 3 (Fig. 3a, b). We selected CAL51 299 
cells in this instance as these cells have a diploid genome and an absence of 300 
large-scale genomic rearrangements. Ten million cells were electroporated with 301 
transposase plasmid and UPATrap-VC 1, 2 and 3 using a limiting dilution of 302 
transposon DNA to maximize the likelihood of a single transposon integration 303 
event per cell (Supplementary Fig. 3b, c, d)22, generating ~50,000 gene-trapping 304 
events after neomycin selection. We divided this library into six sub-libraries and 305 
then transfected each sub-library with either PBZ-GFP, PBZ-VN or PBZ-4A-VN 306 
sensors (Fig. 3a (ii)). The PBZ-GFP construct shows the efficiency of the 307 
electroporation, which was typically in the range of 60-65% (Supplementary Fig. 308 
3e). After culturing cells for 48 hours, GFP-positive cells were isolated by FACS 309 
(Fig. 3a (iii)). Compared to PBZ-GFP, introduction of PBZ-VN caused < 0.1% of 310 
cells to become GFP-positive, as expected for a probe only detecting VC tagged 311 
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PARylated proteins. After isolating genomic DNA (gDNA) from GFP-positive cells, 312 
we identified gene targeting events using an optimized non-restrictive linear 313 
amplification PCR method (nrLAM-PCR)23. This method amplifies the genomic 314 
region adjacent to each UPATrap-VC transposon insertion site, which was then 315 
sequenced using Ion Torrent sequencing. This PCR method was specific, as 316 
PCR products were only obtained from UPATrap-VC transposed cells and not 317 
from non-transposed cells (Supplementary Fig. 3f, g). We developed apipeline to 318 
align and annotate the sequenced reads as a means to identify UPATrap-VC 319 
insertion sites (see Methods). Each gDNA was amplified and sequenced in 320 
triplicate, resulting in a highly specific pattern of distribution of the sequencing 321 
reads (Supplementary Fig. 3h, i). We found that the number of unique DNA reads 322 
generated by triplicate amplification/sequencing procedures for each UPATrap-323 
VC insertion site to be highly correlated (Spearman’s correlation rs>0.98, Fig. 3d). 324 
In total, we identified 400 UPATrap-VC insertion sites in the GFP-positive cells; 325 
50 of these genomic sites were represented with a high number of unique reads 326 
(>30 reads/site), with the rest forming a long-tail distribution in terms of read 327 
depth (Fig. 3e). From these 50, we filtered out genomic loci identified in the PBZ-328 
4A-VN screening arm as likely false positives, as well as those UPATrap-VC 329 
insertion sites unlikely to form genuine gene-VC e.g. those integrations in gene 330 
deserts. The remaining 20 UPATrap-VC insertion sites were located in 17 genes, 331 
with three genes showing two independent integration events: NPM1 332 
(Nucleophosmin, B23), CTIF (Cap binding complex dependent translation 333 
initiation factor) and CCDC171 (Coiled-coil domain containing 171) (Fig. 3f and 334 
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Table 1). Given the low transposon/cell number ratio used, these multiple 335 
insertion events in NPM1, CTIF and CCDC171 originated in different cells and 336 
therefore represented independently occurring events. Due to the complexity of 337 
the screen, and to the depth of sequencing that can be achieved with the nrLAM-338 
PCR, we believe that the screen was conducted in under-saturating conditions. It 339 
is likely that we show a sampling of the PARylome and that further iterations of 340 
the screen would be necessary to achieve saturation. 341 
One of these three genes identified by independent integration events, NPM1, 342 
encodes a known PARylated protein that resides, together with PARP1/2, in the 343 
nucleoli of cells24,25,9. We found that the NPM1-VC + PBZ-VN GFP signal had a 344 
precise nucleolar localization, which partially coincided with endogenous NPM1 345 
as shown by antibody staining (Fig. 3g). The identification of this bona fide 346 
PARylated protein gave us confidence that we have identified genuine 347 
PARylation targets in the screen. We also generated VC sensors for an 348 
additional 10 candidate PARylated target proteins and examined the cellular 349 
localization with the PBZ-VN. In each case, we observed a specific subcellular 350 
localization pattern (Fig. 3h). We validated these localisation patterns in the case 351 
of CTIF (Fig. 3g and the rest of this study) and ILF3 (Supplementary Fig. 2d) by 352 
antibody co-staining, which showed partial overlap with between the protein and 353 
the biosensor. It is important to point out that we have attempted to co-localise 354 
the biosensor signal for a subset of these genes with a staining with PAR-binding 355 
reagent (Millipore). As shown in Supplementary Fig. 2d, in five examined cases 356 
we failed to observe co-staining (with an exception of CTIF where a mild co-357 
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localisation is observed; this point is addressed below). Crucially, two of these 358 
proteins (TERF1 and GLUT4) are validated PARylation targets, which this 359 
staining failed to confirm. This shows that staining with the PAR reagent is not a 360 
reliable way to validate targets, and that the biosensor has the potential to 361 
achieve higher sensitivity. 362 
We chose to further characterise CTIF as it was identified with multiple 363 
transposon integration sites and its biosensor exhibited a specific, perinuclear 364 
localization (Fig. 3g and Fig. 4). 365 
 366 
CTIF is a TNKS-dependent PARylation target 367 
We identified two independent integration sites in the last two introns of the CTIF 368 
gene, generating two C-terminal truncations as shown in Fig. 4a,b,c. Other than 369 
its role in CBP80/20-dependent translation and nonsense mediated RNA decay26, 370 
very little is understood about the function of CTIF. Examination of the CTIF-371 
VC+PBZ-VN (or CHFR-PBZ-VN) sensor signal suggested that CTIF PARylation 372 
was localized to a cluster of peri-nuclear granules (Fig. 4d). Importantly, this 373 
localisation was not observed when PBZ-4A-VN sensor was used 374 
(Supplementary Fig. 4a). The expression of a VN-only fragment, showed a 375 
diffuse cytoplasmic localization (Supplementary Fig. 4a), similar to a full-length 376 
CTIF-GFP sensor (Fig. 4e), suggesting that CTIF was also localized to the 377 
cytoplasm, similar to previous observations26. However, PARylation of CTIF, as 378 
detected by CTIF-VC+PBZ-VN sensors, occurred predominantly in the 379 
centrosomal area of the cell (Fig. 4e). We validated the centrosomal location by 380 
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the expression of centrosomal markers (CETN2-GFP or Cep170-GFP) or 381 
staining for centrosomal markers (CETN3 and gamma-Tubulin) (Fig. 4e). 382 
Interestingly, endogenous CTIF showed enrichment only at the daughter 383 
centriole – it co-localises with one of the CETN2-GFP marked centrioles, but is 384 
completely excluded from the mother centriole, marked by Cep170-GFP (Fig. 4e, 385 
F and Supplementary Fig. 4c). This shows that CTIF has a bona fide centrosome 386 
targeting. This is further substantiated by CTIF-GFP, which shows a broad 387 
cytoplasmic distribution with enrichment at the centrosome (Fig. 4e). In contrast, 388 
CTIF-VC+PBZ-VN biosensor shows strong centrosomal enrichment in an area 389 
surrounding the centrosomal markers used (Fig. 4e).   390 
 391 
One of the transposon insertions in CTIF was predicted to fuse VC to a truncated 392 
CTIF protein comprising the N-terminal 511 out of the 600 amino acids of the full-393 
length protein (CTIF 1-511). We generated a CTIF 1-511-VC sensor, which when 394 
combined with PBZ-VN, generated an identical GFP localisation pattern to full-395 
length CTIF-VC+PBZ-VN (Supplementary Fig. 4b). In order to identify which 396 
PARP superfamily member is responsible for the CTIF biosensor behavior, we 397 
exposed cells to either olaparib (a PARP1/2 inhibitor) or ICR-TNKS-001 (a 398 
tankyrase inhibitor8), and assessed the CTIF-VC+PBZ-VN signal. Whilst the 399 
signal was unaffected by olaparib exposure, its intensity and cellular distribution 400 
was largely suppressed by the tankyrase inhibitor (Fig. 4g). Tankyrase inhibition 401 
did not abolish the ability of CTIF to bind to the centrosome (Supplementary Fig. 402 
4c), but rather abolished the formation of the biosensor signal in the broader area 403 
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surrounding the centrioles. Furthermore, RNA interference-mediated silencing of 404 
TNKS and TNKS2 led to decreased CTIF-VC+PBZ-VN biosensor signal without 405 
affecting the total CTIF level (Fig. 4h,i). CTIF-GFP immunoprecipitation revealed 406 
that CTIF is directly PARylated, and that this PARylation was suppressed by 407 
tankyrase inhibition (Fig. 4j and Supplementary Fig. 4f). Probing the same blots 408 
for the presence of tankyrase failed to identify an interaction. Tankyrase binds its 409 
targets by recognising a canonical motif27. By this definition CTIF posses two 410 
motifs in its N-terminal domain, albeit with a suboptimal sequence (lacking the 411 
critical arginine residue at position +1) (Supplementary Fig. 4d). We generated a 412 
CTIF mutant with the critical amino acids at the +1 and +6 positions in each motif 413 
replaced by alanine and assessed its cellular localisation; no significant change 414 
in the intensity or localisation of the biosensor signal of the mutant was observed 415 
when compared to wild type CTIF (Supplementary Fig. 4e), suggesting that these 416 
two motifs are not genuine tankyrase recognition sequences. Yet, by generating 417 
an allelic series of CTIF-VC sensors with different CTIF deletion events, we 418 
found that the N-terminal 100 amino acids of CTIF were sufficient for the 419 
localization of CTIF-VC+PBZ-VN to the centrosome, while the C-terminal domain 420 
interacts with a pool of cytoplasmic granules (Fig. 4k and Supplementary Fig. 4g). 421 
Taken together, these data suggested that CTIF is a direct target of tankyrase-422 
mediated PARylation, but its recognition may be mediated through interactions 423 
with another proteins, potentially located in the N-terminal portion of the protein. 424 
 425 
CTIF affects the distribution of centrosomal satellites 426 
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To understand the nature of CTIF PARylation, we exploited the ability of a PAR 427 
biosensor to monitor the temporal and subcellular localisation changes in the 428 
passage of a cell cycle. We introduced CTIF-VC+PBZ-VN or CTIF-GFP 429 
biosensors into H2B-Cherry expressing HeLa cells and imaged them over one 430 
cell cycle (Fig. 5a). Whilst CTIF-GFP showed a largely homogeneous 431 
cytoplasmic distribution throughout the cell cycle, the CTIF-VC+PBZ-VN GFP 432 
signal was clustered in granular structures around the centrosome during 433 
interphase (Fig. 5a). As cells progressed towards mitosis the biosensor intensity 434 
increased and coalesced at the centrosome in G2 (Supplementary Fig. 5a); in 435 
mitosis the signal clearly segregated along with the two centrosomes. These 436 
granular structures were transported towards the centrosome in a microtubule-437 
dependent manner as exposure of cells to the microtubule depolymerizing agent 438 
(nocodazole) led to their reversible cytoplasmic dispersal; a microtubule 439 
stabilizing agent (paclitaxel) had no such effect (Fig. 5b). 440 
 441 
Tankyrase is a known regulator of centrosome behavior5,28, and our data 442 
suggested that it PARylaes CTIF. The dynamic pattern of CTIF PARylation was 443 
reminiscent of the behavior of the centrosomal satellites29,30. This prompted us to 444 
further investigate localization of the CTIF biosensors with respect to various 445 
additional centrosomal markers (Fig. 5c). We found that the CTIF-VC+PBZ-VN 446 
surrounded the inner centrosomal markers CETN2, CETN3, PCNT and gamma-447 
tubulin (Fig. 4e and Fig.. 5d). It also occupied the centrosomal area together with 448 
various centrosomal satellite markers (PCM1, Cep131/Azi1, Cep290 and BBS4, 449 
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Fig. 5d), although not co-localizing with them. Tankyrase co-localised with the 450 
CTIF-VC+PBZ-VN biosensor signal (Fig. 5e), supporting our previous data that 451 
suggested that CTIF might be a tankyrase target protein.   452 
 453 
To investigate the functional effect CTIF might have on centrosomal proteins, we 454 
depleted CTIF by RNA interference (RNAi). Whilst CTIF RNAi did not obviously 455 
influence the localisation of inner centrosomal markers (e.g. PCNT, Fig. 456 
5f,h),certain centrosomal satellite proteins (Cep131/Azi1, Cep290 and BBS4) 457 
became less localized (quantification for Cep131/Azi1 is shown in Fig. 5f,g). 458 
Interestingly, other satellite markers (e.g. PCM1 and OFD1) seemed unaffected 459 
(Supplementary Fig. 5b; phenotypes are summarized in Table 2). Tankyrase 460 
depletion had a similar, although less pronounced effect, upon the same subset 461 
of markers (Fig. 5f,g). Taken together with our earlier observations, this data 462 
suggested that CTIF PARylation, most likely via tankyrases, is associated with 463 
centrosomes, and that this tankyrase-CTIF axis might play a role in the 464 
localisation or recruitment of centrosomal satellite proteins.   465 
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Discussion  466 
In this study, we describe a biosensor-based approach to identify PARylation 467 
events and targets. The system we describe possesses several advantageous 468 
qualities. The ability to detect PARylation without the requirement to lyse cells 469 
facilitates the detection of steady state PARylation in living cells but also 470 
temporal and spatial changes in PARylation. These sensors can be integrated 471 
into a genetic screening systems, including the transposon-based system 472 
described here, enabling the detection of novel PARylation related events. Our 473 
data suggest that CTIF is PARylated in the proximity of the centrosome in a 474 
tankyrase-dependent manner..Subsequent work is necessary to investigate 475 
CTIF’s precise role at the centrosome. Intriguingly, CTIF localises to the growing 476 
daughter centriole where localized RNA translation could be associated with the 477 
translation of a subset of necessary proteins,, similarly to what was previously 478 
shown in the case of OFD1 (ref. 31). 479 
 480 
There will be caveats associated with the PAR-biosensors e.g. protein tagging 481 
that may alter normal cellular behavior. Importantly,although we have not 482 
observed gross aggregation of tagged proteins a major concern remains the level 483 
of tagged protein expression, which may cause artefactual phenotypes in the 484 
biosensor system. There exists the possibility that the PAR-binding may stabilise 485 
PARylation events to some extent.  This is advantageous in terms of detecting 486 
transient PARylation events, but might also be problematic if it interferes with 487 
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normal molecular processes. In each case, the observed phenotypes need to be 488 
validated by orthogonal methods.  489 
 490 
Other methods of gene perturbation e.g. CRISPR-Cas9 mediated gene tagging 491 
(e.g. CRISPaint32) or gene mutagenesis (e.g. CRISPR tiling arrays13) could be 492 
integrated intoexperimental workflows that use PAR biosensors. The PBZ-based 493 
biosensors recognise a specific aspect of the PAR chains (the α(1-2) O-494 
glycosidic bond between the ADP-ribose units); other PAR binding domains (e.g. 495 
macrodomains or WWE motifs) recognise different aspects of the PAR chain33. 496 
We envisage that a range of biosensors can be created that  report on different 497 
facets of PAR biology. Finally, PAR biosensors could be adapted to capture 498 
PARylation events in live animals, which lead to better understanding of the 499 
effects of PARP inhibitors in different tissues in vivo.. 500 
 501 
  502 
 503 
 504 
 505 
  506 
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Methods  507 
Cells 508 
CAL51 and HeLa cells were grown in DMEM (Gibco) supplemented with 10% 509 
FBS, penicillin-streptomycin (ThermoFisher). CAL51 PARP1–/– cells were 510 
generated by GE Dharmacon Edit-R Gene Engineering System, by transfecting 511 
with 1 μg Edit-R CRISPR-Cas9 Nuclease Expression Plasmid mixed with 2.5 μl 512 
of 20 μM PARP1 crRNA (GAC CAC GAC ACC CAA CCG GAG UUU UAG AGC 513 
UAU GCU GUU UUG,) and 2.5 μl of tracrRNA (20 uM), using Lipofectamine 514 
3000 reagent according to the manufacturer's instructions (Life Technologies). 515 
Three days post transfection, cells were selected in 100 nM talazoparib for five 516 
days, and surviving cells were FACS sorted to isolate single clones. Biallelic 517 
genome modification was confirmed by Sanger sequencing. HeLa cells 518 
expressing PARP1-LAP construct have been previously described34. 519 
 520 
Constructs  521 
The PAR biosensors are based on the APLF amino acids 371-451 or CHFR 522 
amino acids 407-665 sequence respectively, which were synthesized and cloned 523 
into pEGFP-N1 (Clontech), the EcoRI/KpnI site of pBiFC-VN173 (Addgene 524 
#22010) and pBiFC-VC155 (Addgene #22011, ref. 35), and pcDNA3-mRuby2 525 
(Addgene #40260, ref 36). In the APLF-based biosensor, Cys-to-Ala mutations 526 
were introduced in C379, C385, C421 and C427 to generate the 4A versions of 527 
the above constructs. Full-length FLAG-PARP1 was cloned in pEGFP-N1 vector. 528 
DNA-binding deficient (p.delM43F44I13) and catalytic-deficient mutant (E988K) 529 
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were introduced with site-directed mutagenesis. Hits identified in the PARylation 530 
screen were amplified from a cDNA library and cloned in the pBiFC-VC155 531 
vector. Full-length CTIF was amplified from a cDNA library and cloned in pEGFP-532 
N1 or pBiFC-VC155 vector. CTIFm2 mutant, carrying the following substitutions 533 
– K44A, G49A, L150A and G155A, was produced by gene synthesis and cloned 534 
into the pBiFC-VC155 vector. UPATrap-VC/GFP vectors are based on the 535 
UPATrap technology21. The IRES-GFP moiety of UPATrap-Tmat vectors 1, 2 and 536 
8 (Genbank accession numbers AB673346, AB673347, AB673353) was 537 
replaced by HA-VC155 or HA-EGFP; the HA sequence starts 15 base pairs 538 
downstream of the SA and lacks an ATG codon. To cover the three possible 539 
reading frames, three vectors were created, which have 0, 1 or 2 C bases in front 540 
of the HA sequence. The IRES from the splice donor (SD) cassette was excised 541 
in order to bias the selection of integration sites towards the last introns. CETN2-542 
GFP (#41147) and Cep170-GFP (#41150) expressing constructs were acquired 543 
from Addgene.  544 
 545 
Antibodies 546 
GFP (Roche, 11814460001; 1:2000), PAR 10H (Trevigen, 4335-AMC-050; 547 
1:200), PAR binder (Millipore, MABE1031, 1:1000), CTIF (Sigma-Aldrich, 548 
HPA016865-100UL; 1:1000), TERF1 (Abcam, ab10579; 1:1000), GLUT4 (Abcam, 549 
ab654; 1:1000), ILF3 (Abcam, ab92355; 1:1000), NPM1 (Abcam, ab10530; 550 
1:1000), CETN3 (Abnova, H00001070-M01; 1:500), PCNT (Atlas antibodies, 551 
HPA016820; 1:500), PCM1 (Cambridge bioscience, A301-149A; 1:500), gamma-552 
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tubulin (Sigma-Aldrich, T6557-100UL; 1:500), Azi1/Cep131 (Abcam, ab84864; 553 
1:500), Cep290 (Abcam, ab84870; 1:500), BBS4 (Proteintech, 12766-1-AP; 554 
1:500), OFD1 (Proteintech, 22851-1-AP; 1:500), TNKS1/2 (Santa Cruz, sc-8337; 555 
1:1000), alpha-tubulin (Sigma-Aldrich, T9026; 1:10000), beta-actin (Sigma-556 
Aldrich, A1978; 1:10000).   557 
 558 
Reagents 559 
Olaparib (Selleckchem), ICR-TNKS-001 (ref. 8), Nocodazole (Sigma, M1404-560 
10MG), Paclitaxel, H2O2 (Sigma, 216763-100ML), G418 (Sigma, G8168-100ML). 561 
 562 
siRNA  563 
The following siRNAs were provided by GE Healthcare siCTIF (M-021020-01-564 
0005), siTNKS (M-004740-01-0005), siTNKS2 (M-004741-01-0005). 565 
 566 
Transfection 567 
DNA constructs were transfected with Lipofectamine 2000 (Life Technologies) 568 
according to manufacturer instructions. Typically, for a 24-well plate a mix of 175 569 
ng of gene-VC and 25 ng sensor-VN was transfected. For siRNA transfection 570 
Lipofectamine RNAiMax was used (Life Technologies) according to manufacturer 571 
instructions. 572 
 573 
Immunoprecipitation and western blotting 574 
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Immunoprecipitation was typically carried out from close-to-confluence 10-cm 575 
dishes transfected in advance with appropriate construct. Cells were washed with 576 
PBS, collected and lysed in Net-N buffer (50 mM TrisHCl pH7.5, 1 mM EDTA, 577 
0.5% IGEPAL CA-630, 1 mM DTT, protease inhibitors (Sigma, cOmplete mini), 578 
sonicated and cleared by centrifugation. 0.5-1 mg total protein extract was 579 
incubated with GFP_Trap beads (Chromotek) for 1 hour at 4°C with rotation. 580 
Beads were washed five times with lysate buffer and proteins were eluted by 581 
heat denaturation in loading dye. Samples were resolved on NuPAGE protein 582 
gels (ThermoFisher), transferred to nitrocellulose membrane and blocked in 5% 583 
milk. Anti-PAR (1:2000) and anti-GFP (1:2000) were incubated at 4°C overnight. 584 
Proteins were detected and quantified on the Odyssey Fc imaging system (LiCor).  585 
 586 
Cellular libraries construction and screening 587 
1x107 CAL51 cells were electroporated with 30 ng UPATrap-VC (each open 588 
reading frame) and 1400 ng Tol2 transposase expressing plasmid. They were 589 
split and kept as six independent cellular libraries. The cells were selected with 590 
0.8 mg/ml G418 for 10 days. Colony formation assay showed that each cellular 591 
library contained ~5000 independent clones. Libraries were expanded to a 592 
representation of 1000 cell/clone and frozen down. For the PARylation screen, 593 
each library was divided into three identical aliquots (each aliquot had 5x106 cells, 594 
to ensure ~1000 cells representation for each of the 5,000 VC-gene trap events). 595 
The first aliquot was electroporated with a wild type (PBZ-GFP) biosensor 596 
expression plasmid to monitor the efficiency of electroporation, which was 60%. 597 
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The second aliquot was electroporated with a wild type (PBZ-VN) biosensor 598 
expression plasmid and the third aliquot was electroporated with a mutant (PBZ-599 
4A-VN) VN linked biosensor. After 48 hours, the GFP-positive fraction from the 600 
PBZ-VN and PBZ-4A-VN aliquots (<0.1 % of each library) was isolated by FACS. 601 
These cells were expanded and aliquots were frozen and gDNA prepared (Blood 602 
and Tissue kit, Qiagen). 603 
 604 
nrLAM protocol 605 
nrLAM-PCR protocol was adapted and optimized from ref. 23 as follows. For 606 
each gDNA sample three independent reactions were run. 50 μl reactions, 607 
containing 1.25 U Taq (NEB), 1 μg gDNA, 0.5 μl 0.17 μM biotin-SPL1 primer and 608 
2 μl 0.5 mM dNTPs, were cycled – 95°C/2’, 50x(95°C/45”, 58°C/45”, 72°C/10”). 609 
After one run, 1.25 U Taq was added and the PCR program repeated. 610 
Biotinylated products were collected on streptavidin beads (Life Technologies 611 
11205D), washed and re-suspended in a ligation mastermix, containing 25% w/v 612 
PEG8000 (Sigma 89510-250G-F), 1 μM ssAdapter, 1 mM Co(NH2)6Cl3 (Sigma 613 
H7891-5G), 1x T4 ligation buffer and 20 U T4 ligase (NEB), for 16 h at 25°C and 614 
300 rpm shaking. Reactions were diluted with 90 μl water, beads were collected 615 
and washed with 100 μl water. Finally they were re-suspended in 25 μl water and 616 
5 μl were used in a 50 μl Q5 (NEB) PCR reaction with 0.2 μM SPL-1 and 0.2 μM 617 
HmSp1 primers - 98°C/30”, 20x(98°C/20”, 70°C/20”, 72°C/1’), 72°C/2’. 1 μl of this 618 
PCR reaction was used as a template in a subsequent reaction: 50 μl Q5 PCR 619 
reaction with 0.2 μM P1trunc and 0.2 μM IonTorrent_index primers - 98°C/30”, 620 
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10x(98°C/10”, 61°C/10”, 72°C/1’), 10x(98°C/10”, 69°C/10”, 72°C/1’), 72°C/2’. 621 
PCR products were obtained only from Tol2-containing gDNA. DNA libraries 622 
were purified with a PCR purification kit (Qiagen) and sequenced on Ion Torrent 623 
PGM 318 chip, 400 flow. 624 
Biotin-SPL1 – 5′CATGCATCATATCCATCGCAATCGCATCC  625 
ssAdapter – 5’ 626 
GATCACCGACTGCCCATAGAGAGGGGTCTCTCCTAGCAACGGTTACTCTTC627 
G (NB: 5′-P, phosphorthioate last C-G bond, 3′-C3 blocking group) 628 
SPL-1 – 5′CATGCATCATATCCATCGCAATCGCATCC 629 
HmSp1 – 5′CGAAGAGTAACCGTTGCTAGGAGAGACC 630 
P1trunc – 5′CCTCTCTATGGGCAGTCGGTGATC 631 
AdapterindexTol2-632 
5′CCATCTCATCCCTGCGTGTCTCCGACTCAGN10GATTTTGAGTACTTTTTAC633 
ACCTCTG 634 
 635 
Data analysis 636 
The data analysis pipeline is online in a diagram in Supplementary Fig. 6. Briefly, 637 
fastq files were obtained from Ion Torrent sequencing. The Tol2 sequence 638 
(5′TTTGAGTACTTTTTACACCTCTG) was removed from all the reads by 639 
cutadapt-1.4.2 and they were further aligned to the human genome GRCh37, 640 
using bwa-0.7.9a37. From the alignment bam/bed files were generated. Using 641 
bedtools38 master blocks were generated, covering the coordinates of any 642 
overlapping bed across all sequenced samples. PCR duplicates were removed 643 
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from the bed files and only unique-length reads were counted. Each bed file was 644 
intersected with the master block and with gene annotation bed files. In this way, 645 
one generates a unique integration site identifier (master block) for which unique 646 
reads can be counted for each sample. Finally, the unique-length read count 647 
information was intersected across samples. This generated the initial hit list of 648 
integration sites with their counts.   649 
The initial hit list was subjected to the following filtering criteria. Firstly, integration 650 
sites with less than three unique-length reads were discarded. Secondly, every 651 
authentic integration site should produce a stacked pyramidal arrangement of 652 
reads that have to be co-oriented with the direction of transcription of the host 653 
gene e.g. Supplementary Fig. 3h,i. Hence, anti-oriented sites were discarded. 654 
The sites in the resulting list were further filtered based on the following criteria: 655 
discarded were sites found in the negative control (PBZ-4A-VN sensor), sites 656 
located outside of known genes and sites whose splicing would not lead to the 657 
expression of gene-VC fusion (based on the precise location of the integration 658 
site within a gene). Furthermore, genes with multiple independently identified 659 
integration sites were noted as high-confidence hits. 660 
 661 
Imaging and microirradiation 662 
Cells were seeded on coverslips and transfected with biosensor constructs. After 663 
48 hours incubation, the cells were fixed with 1% PFA solution at room 664 
temperature for 10 min.  Cells were permeabilized with 0.2% Triton X-100 in PBS 665 
and blocked with IFF (2% BSA, 1% FBS in PBS). Antibody incubation was 666 
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carried out in IFF with primary antibody typically in 1:500 dilution; secondary 667 
antibody (alexa594-conjugated, ThermoFisher) was used in 1:1000 dilution. 668 
Cover slips were mounted on ProLong Gold Antifade (ThermoFisher) and 669 
imaged on a Zeiss LSM 780 confocal microscope. 670 
For microirradiation, cells were grown in glass-bottom culture dishes (MaTek, 671 
P35G-0.170-14-C) and transfected with required constructs. 24 hours post 672 
transfection imaging was done on Andor Revolution system, 60x water objective 673 
with micropoint at 365 nm. Measured were only cell with similar intensity of the 674 
GFP signal. The background intensity (in the vicinity of the microirradiation area 675 
in the nucleus) was subtracted from that at the microirradiation point and the 676 
maximum was normalised to 1. For the FRAP experiments the same system was 677 
used with the following FRAPPA settings – dwell time – 60, repeat – 10 and laser 678 
intensity – 6%. 679 
 680 
Data availability 681 
The constructs used in this study are available upon request to the authors or at 682 
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Transposon integration site sequencing data has been deposited at the 684 
European Nucleotide Archive with study number PRJEB26343. 685 
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Figure legends  798 
Figure 1. PAR biosensors detect cellular PARylation. (a) PAR-binding biosensors 799 
derived from APLF and CHFR. The PAR-binding PBZ domains were fused to full-length 800 
GFP, generating PAR biosensors PBZ-GFP and CHFR-PBZ-GFP, respectively. When 801 
CHFR PBZ biosensor is used it is explicitly annotated; in all other cases the APLF PBZ 802 
biosensor is used. (b,c) PAR-binding biosensor signal correlates with PAR 803 
immunodetection but has a greater dynamic range.  HeLa cells expressing PBZ-GFP 804 
were exposed to 1 mM H2O2 or 1 μM olaparib; GFP signal and PAR (10H anti-PAR 805 
antibody) were monitored 10 min after exposure. (b) Scatter plots of the PAR biosensor 806 
intensity correlate with the PAR Ab detection. Intensities were measure in >1000 cells 807 
per condition. (c) Fold change in median signal in H2O2 vs. mock, and olaparib vs. mock 808 
are shown for both PAR detection approaches (exemplary images are shown in 809 
Supplementary Fig. 1.A). NS – not significant, box plot shows quartiles, Student’s t-test 810 
** - p-values<0.01. (d,f) Kinetics of PARylation at sites of DNA damage. PARP1 null 811 
CAL51 cells (CAL51 PARP1–/–) were transfected with PARP1-GFP and PBZ-mRuby2 812 
and exposed to localized (micro)irradiation as shown in (d). After microirradiation, 813 
PARP1 and PAR localisation were monitored over time. A microirradiated cell is shown; 814 
the area that is shown on the subsequent kymographs is annotated with a white box with 815 
a 2 µm side. Scale bar represents 5 µm. (e) Kymograph (top) and graph (bottom) of 816 
PARP1 and PBZ-mRuby2 0-3 s after microirradiation. (f) as per (e) but 0-10 minutes 817 
after microirradiation. Each graph shows average signals from >10 cells; scale bar 818 
represents a distance of 2 µm. (g,h) A PAR biosensor detects loss of PAR at 819 
microirradiated sites caused by PARP1 mutations. (g) PARP1 bound to a double strand 820 
break (4OQB) with indicated: p.[43delM;44F>I] and E988K mutations in red. (h) 821 
Kymographs are shown from microirradiated CAL51 PARP1–/– cells expressing PBZ-822 
mRuby2 and either wild type PARP1-GFP, PARP1-p.[43delM;44F>I]-GFP, or PARP1-823 
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E988K-GFP. (i) The clinical PARP inhibitor talazoparib reduces PAR levels at sites of 824 
microirradiation. Kymographs of HeLa cells with a PARP1-GFP containing bacterial 825 
artificial chromosome (PARP1-LAP) and PBZ-mRuby2 were exposed to 100 nM 826 
talazoparib for 1 h prior to microirradiation. 827 
 828 
 829 
Figure 2. Bimolecular fluorescent complementation (BiFC) PAR biosensors detect 830 
cellular PARylation. (a) BiFC PAR biosensor - PBZ coding sequence was fused to the 831 
N-terminus of Venus (VN) (PBZ-VN); the C-terminus of Venus (VC) was fused to query 832 
protein (protein-VC). PARylation of the query protein leads to VC-VN interaction and 833 
restoration of a fluorescent GFP. (b) HeLa cells were transfected with constructs 834 
expressing: VN + VC, PBZ-VN, PBZ-VC, PBZ-VN + PBZ-VC or PBZ-4A-VN + PBZ-4A-835 
VC (4A constructs lack PAR binding). Cells were mock-treated or exposed to 1 mM H2O2 836 
and stained with PAR-binding reagent (Millipore). GFP nuclear foci are observed only in 837 
the PBZ-VN + PBZ-VC, and are marked by PAR-binder staining. (c) A quantification of 838 
PAR nuclear intensity as shown in (b). GFP+ and GFP- represents the PAR intensity of 839 
sensor-transfected or not-transfected cells. PBZ-VN + PBZ-VC expression leads to PAR 840 
accumulation in the absence of damage. Mean and standard deviations are shown for 841 
>20 nuclei. (d) Confocal images of PARP1 wild type or PARP1–/– CAL51 cells 842 
expressing, PBZ-VN + PBZ-VC or PBZ-4A-VN + PBZ-4A-VC. PBZ-4A. Loss of PARP1 843 
or PARP1 inhibition (olaparib) ablated the formation of nuclear GFP foci, whilst the 844 
tankyrase inhibitor (ICR-TNKS-001) did not; mean nuclear GFP intensity from >20 845 
nuclei; box plot shows quartiles, ** - Student’s t-test p-values<0.01. (e) Kinetics of 846 
PARylation at microirradiation sites. Kymographs and graphs of the GFP signal in 847 
PARP1 wild type or PARP1–/– CAL51 cells with either PBZ-VN + PBZ-VC sensors or 848 
PBZ-4A-VN + PBZ-4A-VC sensors. (f) The PARP inhibitor talazoparib modulates PAR 849 
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foci. HeLa cells, expressing PBZ-VN + PBZ-VC, were exposed to 100 nM talazoparib 850 
overnight; the cells were washed in drug-free media and imaged. After removal of 851 
talazoaprib, biosensor signal in the cytoplasm (yellow arrow) reduced; whilst the 852 
frequency of GFP+ nuclear foci (red arrows) increased. (g) PAR Biosensor detects 853 
nuclear/cytoplasmic localisation patterns of known PARylated proteins. HeLa cells were 854 
co-transfected with PBZ-VN or PBZ-4A-VN plus AXIN-VC, TERF1-VC, TNKS2_800-855 
1161-VC or GLUT4-VC. PBZ-VN transfected cells revealed protein-specific localisation 856 
pattern, whilst PBZ-4A-VN transfected cells did not. Scale bars represent 5 µm. 857 
 858 
Figure 3. A transposon-based biosensor screen to identify PARylated proteins. (a) 859 
A genetic screen to identify PARylation events. (i) UPATrap-VC was introduced into 860 
CAL51 cells, generating six tagged cell libraries (5000 clones each). (ii) Either PBZ-GF, 861 
PBZ-VN or PBZ-4A-VN biosensors were introduced into each library and GFP-positive 862 
cells were isolated (iii); PBZ-GFP showed 60% GFP-positive cells, while the PBZ-VN 863 
constructs showed 0.1% GFP-positive cells. (iv) Genomic DNA was isolated from GFP-864 
positive cells and UPATrap-VC integration sites identified by non-restrictive linear 865 
amplification PCR (nrLAM-PCR) followed by deep sequencing. Each gDNA sample was 866 
amplified and sequenced in three independent reactions (A, B, C). (b) A schematic of 867 
the transposon-mediated VC tagging, when an UPATrap-VC transposon is introduced 868 
into genes. Yellow triangles = Tol2 transposon repeats; SA = splicing acceptor; SD = 869 
splicing donor, IRES = internal ribosome entry site, NeoR = G418-resistance gene; pA = 870 
polyAdenylation signal. Integration of UPATrap-VC into genes results in the production 871 
of protein-VC fusion proteins and NeoR protein. (c) Integration of a full-length GFP 872 
version of UPATrap (UPATrap-GFP) generates specific localisation pattern in different 873 
GFP-positive colonies. This suggests that the transposon has captured and generated 874 
in-frame protein-VC fusion in a specific gene. (d) nrLAM-PCR and deep sequencing 875 
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from independent reactions is highly reproducible. Scatter plots are shown illustrating the 876 
correlation between unique read depth from three replica nrLAM-PCR and sequencing 877 
reactions (A, B and C); Spearman’s rank correlation >0.98. (e) Distribution of sequencing 878 
depth across all libraries in the screen. Approximately 50 genomic sites were 879 
represented by a unique read depth of >30 reads (see detailed description in methods). 880 
(f) A schematic representation of the three genes identified with two, independent, 881 
transposon integration sites (indicated by red circles). (g) Biosensor signal obtained by 882 
the expression of full-length NPM1-VC and CTIF-VC in combination with PNZ-VN. The 883 
cells were co-stained with antibodies, recognizing the endogenous NPM1 and CTIF, 884 
respectively. (h) PARylation biosensor screen detects “hits” with different subcellular 885 
localisation. Confocal imaging of VC-VN GFP signal for 11 genes identified in the screen 886 
are shown. NPM1 is a known PARylation target. Scale bars represent 5 µm. 887 
 888 
Figure 4. CTIF is PARylated in a TNKS-dependent manner. A schematic of the CTIF 889 
3´ end with Tol2 integration sites (red circles) (a), nrLAM-PCR products (b) and 890 
generated CTIF-VC fusion proteins (c) identified in the screen. (d) CTIF biosensor is 891 
localises to the centrosomal area of the cell (white arrowheads). HeLa cells were 892 
transfected with CTIF-VC + PBZ-VN or CHFR-PBZ-VN and immunostained with an anti-893 
CTIF antibody. (e) CTIF localises with centrosomal markers. HeLa cells were transfected 894 
with centrosome markers CETN2-GFP or Cep170-GFP, and co-stained with anti-CTIF 895 
antibody. Cells expressing either CTIF-GFP or (CTIF-VC + PBZ-VN) were co-stained 896 
with anti-CETN3 or anti-γTubulin. CTIF-GFP is broadly distributed in the cells, while the 897 
CTIF biosensor is surrounding the centrosome. White arrowheads indicate the area that 898 
is shown in insets with 2 µm side. (f) CTIF localises to the daughter centriole. HeLa cells 899 
were transfected with CETN2-GFP (marks both centrioles) or Cep170-GFP (marks the 900 
mother centriole), and stained with anti-CTIF antibody. (g) Tankyrase inhibition reduces 901 
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CTIF biosensor signal. HeLa cells, expressing CTIF-VC + PBZ-VN, were exposed to 902 
olaparib or ICR-TNKS-001. Quantification of the GFP signal over >20 cells in three 903 
independent experiments is shown, NS – not significant, box plot shows quartiles, ** - 904 
Student’s t-test p-values<0.01. (h) Tankyrase depletion reduces CTIF biosensor signal, 905 
as in (g) TNKS + TNKS2 siRNA did not reduce CTIF expression (CTIF-GFP). The 906 
efficiency of depletion is shown on the Western blot in panel (i). (j) CTIF is a direct 907 
PARylation target. CTIF-GFP was immunoprecipitated with anti-GFP antibody and 908 
immunoblotted with anti-PAR (10H) antibody. Uncropped blots are shown in 909 
Supplementary Fig. 4.F. (k) CTIF has a N-terminal CBP80 (AA 1-305) and a C-terminal 910 
MIF4G (AA 380-600) domain. A deletion series was fused to either full-length GFP or VC 911 
sequence. CAL51 cells, expressing GFP-fused variants showed broad cytoplasmic 912 
distribution, whilst the VC-fused ones showed localized patterns. Centrosome signal was 913 
observed with the full length CTIF, and with the N-terminal CBP80 domain, down to the 914 
100 most N-terminal amino acids (white arrows). All constructs were expressed at a 915 
similar protein level (Supplementary Fig. 4g). Scale bars represent 5 µm. 916 
 917 
Figure 5. CTIF modulates centrosomal satellites. (a) CTIF biosensor localises and 918 
segregates with the centrosome. Live cell imaging of H2B-cherry HeLa cells expressing 919 
either CTIF-GFP or CTIF-VC + PBZ-VN showed that CTIF-GFP is distributed throughout 920 
the cytoplasm during M phase (top images), whilst CTIF-VC + PBZ-VN signal (lower 921 
images) segregated with the centrosome during mitosis. Detailed time series are shown 922 
in Supplementary Fig. 5a. (b) CTIF biosensor localisation is microtubule-dependent. 923 
HeLa cells expressing CTIF-VC + PBZ-VN were exposed to either nocodazole or 924 
paclitaxel. Nocodazole caused a reversible dispersal of the signal whilst the microtubule-925 
stabilising drug paclitaxel did not. (c) Schematic illustrating the centrosome with a central 926 
pair of centrioles, surrounded by pericentrosomal material (PCM), microtubules (MT) and 927 
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centrosomal satellites (CS). (d) Co-localisation of CTIF biosensor and various 928 
centrosomal markers showed that PARylated CTIF is peripheral to inner centrosomal 929 
markers (CETN3 and PCNT) and PCM (PCNT and PCM1), whilst it is localised in the 930 
area occupied by the centrosomal satellites (Cep131/Azi1, Cep290 and BBS4); insets 931 
are with 2 µm sides. (e) CTIF PARylation biosensor co-localises with tankyrase. HeLa 932 
cells transfected with CTIF-VC + PBZ-VN were immunostained for endogenous 933 
tankyrase; scale bars in the zoomed images represent 1 μm. (f) CTIF depletion affects 934 
the centrosomal satellites, but not the core centrosome. HeLa cells were depleted by 935 
CTIF or tankyrase (TNKS + TNKS2) siRNA and immunostained for various centrosomal 936 
markers. Images show staining for the centrosomal satellite marker Cep131/Azi1 and for 937 
the core centrosome marker PCNT together with centrosomal marker γTubulin. Images 938 
for all the other analyzed markers are shown in Supplementary Fig. 5b and full summary 939 
is provided in Table 2. The average intensity of the signal at the centrosomal area was 940 
quantified in n = 150 nuclei and normalized to the median of the mock-transfected cells. 941 
Box plot shows that CTIF depletion, and to a lower extend tankyrase depletion, leads to 942 
the dispersal of the centrosomal satellite (Cep131/Azi1 quantified in (g)), whilst not 943 
affecting the core centrosome (PCNT quantified in (h)); box plot shows quartiles, p-944 
values were calculated by two-sided Student’s t-test. Scale bars represent 5 µm. 945 
 946 
 947 
 948 
 949 
 950 
  951 
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Table 1. A summary of the Tol2 integration sites identified in the PARylation 952 
screens. The position of the integration, the host gene information, the number of 953 
the unique-length reads obtained by the nrLAM-PCR, and the length of the N-954 
terminally truncated fragment for each protein are shown for each insertion site. 955 
Chr 
Strand 
orientati
on 
Insertion 
site 
(genomic 
position) 
Median_
read_sa
mple 
Nr 
Insertion 
sites 
Gene  Gene ID 
Truncati
on (N-
terminal 
AA) 
Protein 
length 
(AA) 
5 + 170827447 502 2 NPM1 
ENSG000
0018116
3 
195 259 
5 + 170823418 321 2 NPM1 
ENSG000
0018116
3 
174 259 
18 + 46304668 1131 2 CTIF 
ENSG000
0013403
0 
459 600 
18 + 46366092 777 2 CTIF 
ENSG000
0013403
0 
551 600 
9 + 15888921 471 2 CCDC171 
ENSG000
0016498
9 
1200 1326 
9 + 15887412 361 2 CCDC171 
ENSG000
0016498
9 
1200 1326 
1 + 95306653 972 1 SLC44A3 
ENSG000
0014303
6 
253 653 
8 - 119229899 612 1 SAMD12 
ENSG000
0017757
0 
155 161 
6 + 25600895 572 1 LRRC16A 
ENSG000
0007969
1 
1039 1371 
5 - 76998018 420 1 TBCA 
ENSG000
0017153
0 
55 108 
19 + 39122699 377.5 1 EIF3K 
ENSG000
0017898
2 
119 218 
3 - 30786048 376 1 GADL1 
ENSG000
0014464
4 
464 521 
19 - 40368616 339.5 1 FCGBP 
ENSG000
0009092
0 
4157 5405 
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9 + 130443026 313.5 1 STXBP1 
ENSG000
0013685
4 
515 594 
3 + 142745673 166 1 U2SURP 
ENSG000
0016371
4 
426 1029 
19 + 10797868 144 1 ILF3 
ENSG000
0012935
1 
690 702 
2 - 45729067 80 1 SRBD1 
ENSG000
0006878
4 
624 995 
3 + 29904702 43.5 1 RBMS3 
ENSG000
0014464
2 
212 433 
3 + 155641886 38 1 GMPS 
ENSG000
0016365
5 
478 693 
4 + 71665115 22 1 RUFY3 
ENSG000
0001818
9 
520 620 
 956 
Table 2. A summary of the CTIF and tankyrase (TNKS + TNKS2) depletion 957 
phenotypes on various centrosomal markers. Various centrosomal markers were 958 
immunodetected (as in Fig.Fig. 5d) after RNAi-mediated depletion of either CTIF, 959 
or TNKS + TNKS2 in either HeLa, or CAL51 cells. “+” denotes localisation similar 960 
control depleted cells, “+/-” denotes diminished centrosomal localisation, “-” 961 
denotes absent or severely diminished centrosomal localisation. 962 
Marker protein CETN3 PCNT PCM1 BBS4 Cep290 Cep131 Azi1 OFD1 
TNKS 
TNKS2 
CTIF-
VC 
WT-
VN 
Localisation Centrioles Centrioles PCM 
PCM      
CS CS CS CS CS   
RNAi 
siCon + + + + + + + + + 
siTNKS + siTNKS2 + + + +/- +/- +/- + - - 
siCTIF + + + - - - + + - 
 963 
 964 
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